The Early Bird

Saranas Reaches Midpoint for Enrollment in Clinical Trial Assessing the Utility of Early Bleed Detection in Patients Undergoing Mechanical Circulatory Support

Retrieved on: 
Monday, March 27, 2023
Cardiology, Surgery, Health, FDA, Medical Devices, Health Technology, Clinical Trials, Other Health, CRF, Bleeding, De novo, Morristown Medical Center, Classification, BARC, Henry Ford Health, Structural heart disease, PCI, Incidence, Henry Ford, Patient, Impella, TAVR, Early Bird, Research, The Early Bird, MCS, Early, EVAR, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, III, Aortic stenosis, Food, Safety, Medical device, Birth control

The Early Bird Bleed Monitoring System is the first and only FDA-approved bleed detection system.

Key Points: 
  • The Early Bird Bleed Monitoring System is the first and only FDA-approved bleed detection system.
  • Patients undergoing complex high-risk PCI with mechanical circulatory support (MCS) via Impella and transfemoral arterial approach are enrolled as study participants.
  • “This is an important milestone in our efforts to continue building clinical evidence to support the utility of the Early Bird device.
  • The Saranas Early Bird Bleed Monitoring System is the first and only FDA-approved device for real-time monitoring of endovascular bleed complications.

Saranas Announces Over 1,200 Patients Treated with the Early Bird® Bleed Monitoring System

Retrieved on: 
Wednesday, November 9, 2022
Surgery, Health, Medical Devices, CT, ST, Morristown Medical Center, Aortic valve, Femoral artery, MCS, Food, JAMA Cardiology, Adoption, FIH, Detection, Structural heart disease, Classification, Bleeding, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Mortality, Early Bird, Cardiology, Early, Length of stay, Patient, Physician, De novo, EVAR, The Early Bird, TAVR, FDA, Trial of the century, Medical imaging, Birth control

Saranas, Inc. announced today that over 1,200 patients have been treated with the Early Bird Bleed Monitoring System, the first and only FDA-approved bleed detection system.

Key Points: 
  • Saranas, Inc. announced today that over 1,200 patients have been treated with the Early Bird Bleed Monitoring System, the first and only FDA-approved bleed detection system.
  • The adoption of the Early Bird system is a testimony to physicians embracing the benefits of early bleed detection for their patients and practice.
  • The Early Bird Bleed Monitoring System includes a bleed detection array with integrated electrodes in a fully functional vascular access sheath.
  • First-in-Human Study of the Saranas Early Bird Bleed Monitoring System for the Detection of Endovascular Procedure-Related Bleeding Events.

Saranas® Receives Innovative Technology Contract from Vizient

Retrieved on: 
Thursday, April 7, 2022
Biotechnology, Surgery, Medical Devices, Hospitals, Health, Academic health science centre, Bleeding, TAVR, Multimedia, Early Bird, Aortic valve, Sarana Chatushtai, Review, The Early Bird, The Queen's Award for Enterprise: Innovation (Technology) (2011), Physician, Patient safety, Internal bleeding, FDA, Femoral artery, Medicine, Birth control, Pharmaceutical industry, Vizient, Inc.

Saranas announced its Early Bird Bleed Monitoring System has received an Innovative Technology contract from Vizient, Inc. , the nations largest member-driven health care performance improvement company.

Key Points: 
  • Saranas announced its Early Bird Bleed Monitoring System has received an Innovative Technology contract from Vizient, Inc. , the nations largest member-driven health care performance improvement company.
  • Innovative Technology contracts are recommended after review and interaction with products submitted through Vizients Innovative Technology Program.
  • Congratulations to Saranas for being awarded an Innovative Technology contract, said Kelly Flaharty, director of contract process for Vizient.
  • Through its Innovative Technology Program , Vizient works with member-led councils and task forces to evaluate products for their potential to bring real innovation to healthcare.

Saranas® Expands Intellectual Property with Key Patent Integrating Bleed Monitoring and Vascular Access Closure Device

Retrieved on: 
Wednesday, February 23, 2022
Biotechnology, Surgery, Medical Devices, Hospitals, Health, Physician, Patent, Hemostasis, Failure, Early Bird, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, The Early Bird, Research, Femoral artery, USPTO, Aortic valve, Medical director, Bleeding, Internal bleeding, Patent ductus arteriosus, FDA, The Christ Hospital, Carl, TAVR, Technology, Standard of care, Birth control, Medical imaging, Sarana Chatushtai, the Early Bird Bleed Monitoring System, Saranas, THE EARLY BIRD BLEED MONITORING SYSTEM, SARANAS

Titled Access Closure with Bleed Monitoring, this key patent allows for embedding a vascular access closure device with the companys proprietary bleed monitoring technology.

Key Points: 
  • Titled Access Closure with Bleed Monitoring, this key patent allows for embedding a vascular access closure device with the companys proprietary bleed monitoring technology.
  • Saranas Early Bird Bleed Monitoring System is the first and only FDA-approved device for real-time detection and monitoring of endovascular bleed complications.
  • This patent award demonstrates Saranas commitment to innovation and further strengthens our intellectual property portfolio.
  • The Early Bird Bleed Monitoring System includes a bleed detection array with integrated electrodes in a fully functional vascular access sheath.

Saranas® Awarded Multiple Purchasing Contracts with Large Healthcare Systems

Retrieved on: 
Wednesday, January 5, 2022
Biotechnology, Hospitals, Health, Medical Devices, Dignity, Overalls, Early, Early Bird, Femoral artery, Department of Defense Office of Inspector General, The Early Bird, Settlement (finance), Physician, Bleeding, DAPA, CommonSpirit Health, Contract, IDN, Department, Hospital, FDA, Aortic valve, Technology, United States Department of Defense, CHI, Dignity Health, Internal bleeding, TAVR, Catholic (term), Health insurance, Birth control, Medical imaging, Sarana Chatushtai, the Early Bird Bleed Monitoring System, Saranas, THE EARLY BIRD BLEED MONITORING SYSTEM, SARANAS

Saranas announces today the closing of the companys two largest Integrated Delivery Network (IDN) contracts and agreements signed to date: CommonSpirit Health and the Department of Defense.

Key Points: 
  • Saranas announces today the closing of the companys two largest Integrated Delivery Network (IDN) contracts and agreements signed to date: CommonSpirit Health and the Department of Defense.
  • CommonSpirit Health, encompassing all Catholic Health Initiative (CHI) and Dignity Health hospitals, has awarded Saranas a multi-year contract for the use of the Early Bird Bleed Monitoring System through Premiers Supply Chain Advisor platform.
  • In addition, Saranas has been approved for a Distribution and Pricing Agreement (DAPA) by the Department of Defense (DoD) for the use of the Early Bird.
  • Saranas Early Bird Bleed Monitoring System is the first and only FDA-approved device for real-time detection and monitoring of endovascular bleed complications.

Saranas® Announces Initial Enrollment of Clinical Trial Assessing the Utility of Early Bleed Detection in Patients Undergoing Mechanical Circulatory Support

Retrieved on: 
Monday, December 6, 2021
Medical Devices, Health, Surgery, Clinical Trials, Cardiology, Biotechnology, Patient, Research, The Early Bird, Atlantic Health System, TAVR, Safety, Femoral artery, Bleeding, Henry Ford Health System, MCS, Aortic valve, PCI, JAMA Cardiology, Morristown Medical Center, Internal bleeding, Physician, Patient safety, BARC, Henry Ford, Incidence, Early Bird, CRF, Mortality, FDA, III, EVAR, Length of stay, Pharmaceutical industry, Medical device, Birth control, Medical imaging, the Early Bird Bleed Monitoring System, Saranas, THE EARLY BIRD BLEED MONITORING SYSTEM, SARANAS

Patients undergoing complex high-risk PCI with MCS via Impella and transfemoral arterial approach will be enrolled as study participants.

Key Points: 
  • Patients undergoing complex high-risk PCI with MCS via Impella and transfemoral arterial approach will be enrolled as study participants.
  • The Early Bird Bleed Monitoring System will be used in the ipsilateral femoral vein to monitor bleeding events after MCS removal.
  • Saranas is committed to building objective evidence to support the clinical utility of the Early Bird device.
  • The Early Bird Bleed Monitoring System includes a bleed detection array with integrated electrodes in a fully functional vascular access sheath.